Bondronat 6mg

Bondronat 6 mg Injection contains Ibandronic Acid (Ibandronate), a powerful bisphosphonate used to treat bone metastases (cancer spread to bones) and hypercalcemia of malignancy (high blood calcium levels caused by cancer).

In patients with metastatic bone disease, the balance between bone formation and resorption is disrupted, leading to bone pain, fractures, and elevated calcium. Bondronat works by inhibiting osteoclast-mediated bone resorption, helping to stabilize bone, reduce pain, lower calcium levels, and prevent skeletal-related complications.

Uses of Bondronat 6 mg

✅ Bone Metastases in Breast Cancer and Other Solid Tumors — reduces skeletal complications
✅ Hypercalcemia of Malignancy — lowers dangerously high calcium levels
✅ Osteolytic Lesions in Multiple Myeloma (in some cases, as part of bisphosphonate therapy)

Key Benefits

• Reduces bone pain and risk of pathological fractures in cancer patients

• Lowers elevated blood calcium due to cancer, preventing kidney and neurological damage

• Supports overall bone health in patients with bone involvement

• Used alongside anticancer therapies to improve quality of life

• Administered under hospital supervision for precise dosing and monitoring

How Bondronat Injection Works

Ibandronic acid is a bisphosphonate that binds strongly to bone minerals and inhibits osteoclast activity — the cells responsible for bone breakdown. By suppressing bone resorption, it slows down the release of calcium from bones into the blood, reduces skeletal complications, and helps maintain stronger, more stable bones in cancer patients.

Dosage & Administration

• Administered as a slow intravenous infusion over 15–30 minutes

• Common dosing: 6 mg every 3–4 weeks for bone metastases

• For hypercalcemia: single 2–4 mg dose, may be repeated if needed

• Adequate hydration before and after infusion is essential to protect kidneys

• Treatment performed in hospital or clinic under doctor supervision